secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptevo Therapeutics Inc. (APVO)
CIK:        0001671584
Form:       8-K
Filed at:   2023-03-30T23:59:59+00:00
Accession:  0000950170-23-010752
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 1.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aptevo raises $9.6M non-dilutive by selling IXINITY payment rights to XOMA; repays debt
--------------------------------------------------------------------------------

- Sold all future IXINITY deferred payments and a portion of milestones to XOMA for $9.6M closing payment.
- Retains rights to up to $5.8M in additional milestones (Canadian, European, net sales) through 2035.
- Used part of proceeds to fully repay and terminate MidCap credit agreement, becoming debt-free.
- Pro forma cash ~$26M, extending runway beyond 12 months; additional $50K possible if Q1 2023 deferred payment exceeds $500K.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671584/000095017023010752/0000950170-23-010752-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671584/000095017023010752/apvo-20230329.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-010752

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer